about
Cell-free DNA as a diagnostic marker for cancer: current insightsImpact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.The potential use of urine cell free DNA as a marker for cancer.Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic ImplicationsUrine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.Serum and Plasma Copy Number Detection Using Real-time PCR.GSTP1 methylation in cancer: a liquid biopsy biomarker?Plasma AR and abiraterone-resistant prostate cancer.Plasma androgen receptor and serum chromogranin A in advanced prostate cancerOxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerPlasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerRe: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:2Epigenetic Characterization of Cell-Free DNACarcinosarcoma of the prostate: case report with molecular and histological characterizationPlasma Androgen Receptor in Prostate CancerImmune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional ApproachesReclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical managementPlasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerTestosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide
P50
Q28074556-6A54BB79-B468-434A-947A-8232806A50EDQ38620751-4BD9638C-E7AC-43A2-83A6-B503D2C300ADQ38804089-7FE8B19E-E998-4883-BE36-288DBF64F785Q38833996-87BAFA77-707E-4364-9C53-D2233552DB9BQ38994581-86676198-C8B8-4310-A1EA-C581C455BA95Q40374954-6303C146-2C85-442F-917D-179BEDA4B3F7Q40985522-F45762AC-8DF6-4673-B7F7-C3014D998B89Q41339288-C3E5E283-95C4-46B5-9A2A-45958D284005Q43169980-E07C353C-1175-4681-9B78-041CA3C7B143Q44453209-3B37AE6C-F1B3-4B38-B680-C93CAB17D3D9Q48510469-789C7F9E-9A3D-43CC-9351-55A8AAB38EA1Q50157056-9F8F4793-470B-49A8-98D8-310CCD7F5550Q53810482-1EE11349-FF8F-47A7-9E75-28AF0709A33AQ58603582-25AB7049-F0A2-455E-8E65-54A54141CBC6Q60043870-2A35797E-A17A-4C8D-A478-C676FA5D8D85Q64076389-1C5E9C52-6ABF-4BCC-9494-7779F4D5C477Q88871694-AF20F45A-E6DD-47FD-96CE-10CB336E57B4Q90723551-C7EDCECA-4E01-433F-A116-74FA7D98DBD6Q90911185-A03D01E2-2689-4CD8-8BC2-C8D1B6BAB421Q91125795-DCF0E0EE-6799-49A6-91B2-9C0193A1C091Q92305209-7EBCE279-92FA-4411-9C1C-C6ADBB7AD0D7Q92423202-3EC20EB9-C6E7-45ED-BBDD-6BF20DEDBC69Q92754681-5DA4585D-0AF0-427D-904C-595743DE9940Q93103855-B2E743D0-C962-4580-ADD5-31FBB7DFA7F3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
G Gurioli
@en
G Gurioli
@nl
type
label
G Gurioli
@en
G Gurioli
@nl
prefLabel
G Gurioli
@en
G Gurioli
@nl
P31
P496
0000-0003-4036-5568